Intratio
Loading...
Skip to main content
Model output · Signal date Oct. 16, 2026

Daily Signals

2758 companies scored · Total · absolute moveSwitch to Alpha · 30D 90D

Signal date 2026-10-16 Cut-offs from the 2026-10-16 run
Companies scored 2758 IC ≥ 0 · market cap ≥ $100M
Median forecast +2.43% Total · 90D
Long–short spread +6.48% Strong Buy minus Strong Sell, mean
Median IC 0.27 Spearman · 90D
Rating changes ▲ 171 ▼ 378 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

296 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
101 PRGOPERRIGO Co plc Life Sciences 0.67 $2.3B Unlock rating and forecasts
102 PGENPRECIGEN, INC. Life Sciences 0.32 $2.3B Unlock rating and forecasts
103 HRMYHarmony Biosciences Holdings, Inc. Life Sciences 0.49 $2.2B Neutral +0.99% +2.78% ·
104 SUPNSUPERNUS PHARMACEUTICALS, INC. Life Sciences 0.10 $2.2B Neutral +0.92% +2.66% ▼ 1
105 AUPHAurinia Pharmaceuticals Inc. Life Sciences 0.11 $2.2B Unlock rating and forecasts
106 CLDXCelldex Therapeutics, Inc. Life Sciences 0.15 $2.2B Unlock rating and forecasts
107 VRDNViridian Therapeutics, Inc.\DE Life Sciences 0.46 $2.2B Neutral +0.63% +2.22% ▼ 1
108 VCELVericel Corp Life Sciences 0.40 $2.1B Neutral +0.54% +1.96% ·
109 SLSSELLAS Life Sciences Group, Inc. Life Sciences 0.41 $2.0B Unlock rating and forecasts
110 BCRXBIOCRYST PHARMACEUTICALS INC Life Sciences 0.23 $2.0B Unlock rating and forecasts
111 LKFTLakefront Biotherapeutics NV Life Sciences 0.38 $2.0B Neutral +0.60% +2.07% ·
112 TRLVTrulieve Cannabis Corp. Life Sciences 0.56 $1.9B Neutral +1.12% +3.23% ▼ 1
113 XERSXeris Biopharma Holdings, Inc. Life Sciences 0.00 $1.9B Unlock rating and forecasts
114 IMNMImmunome Inc. Life Sciences 0.22 $1.9B Unlock rating and forecasts
115 AGIOAGIOS PHARMACEUTICALS, INC. Life Sciences 0.14 $1.9B Neutral +0.88% +2.55% ·
116 NVAXNOVAVAX INC Life Sciences 0.13 $1.9B Unlock rating and forecasts
117 MLYSMineralys Therapeutics, Inc. Life Sciences 0.24 $1.8B Unlock rating and forecasts
118 ALVOAlvotech Life Sciences 0.17 $1.8B Unlock rating and forecasts
119 MRVIMARAVAI LIFESCIENCES HOLDINGS, INC. Life Sciences 0.68 $1.8B Unlock rating and forecasts
120 PVLAPALVELLA THERAPEUTICS, INC. Life Sciences 0.13 $1.7B Unlock rating and forecasts
121 XNCRXencor Inc Life Sciences 0.29 $1.7B Unlock rating and forecasts
122 TRVITrevi Therapeutics, Inc. Life Sciences 0.30 $1.7B Unlock rating and forecasts
123 URGNUroGen Pharma Ltd. Life Sciences 0.55 $1.7B Unlock rating and forecasts
124 VIRVir Biotechnology, Inc. Life Sciences 0.36 $1.7B Unlock rating and forecasts
125 SDGRSchrodinger, Inc. Life Sciences 0.35 $1.7B Unlock rating and forecasts
126 ANIPANI PHARMACEUTICALS INC Life Sciences 0.58 $1.7B Unlock rating and forecasts
127 NTLAIntellia Therapeutics, Inc. Life Sciences 0.43 $1.6B Unlock rating and forecasts
128 PAHCPHIBRO ANIMAL HEALTH CORP Life Sciences 0.32 $1.6B Unlock rating and forecasts
129 NUVBNuvation Bio Inc. Life Sciences 0.10 $1.6B Unlock rating and forecasts
130 STOKStoke Therapeutics, Inc. Life Sciences 0.20 $1.6B Unlock rating and forecasts
131 GENBGenerate Biomedicines, Inc. Life Sciences 0.20 $1.6B Unlock rating and forecasts
132 QUREuniQure N.V. Life Sciences 0.12 $1.5B Unlock rating and forecasts
133 OCULOCULAR THERAPEUTIX, INC Life Sciences 0.08 $1.5B Unlock rating and forecasts
134 INVAInnoviva, Inc. Life Sciences 0.07 $1.5B Unlock rating and forecasts
135 KRSAKorsana Biosciences, Inc. Life Sciences 0.15 $1.5B Unlock rating and forecasts
136 CMPSCOMPASS Pathways plc Life Sciences 0.34 $1.5B Unlock rating and forecasts
137 PCRXPacira BioSciences, Inc. Life Sciences 0.27 $1.4B Unlock rating and forecasts
138 ETONEton Pharmaceuticals, Inc. Life Sciences 0.10 $1.4B Unlock rating and forecasts
139 RAREUltragenyx Pharmaceutical Inc. Life Sciences 0.14 $1.4B Unlock rating and forecasts
140 COAGHemab Therapeutics Holdings, Inc. Life Sciences 0.46 $1.4B Neutral +0.61% +2.18% ·
141 ANABANAPTYSBIO, INC Life Sciences 0.27 $1.4B Neutral +1.11% +3.15% ·
142 RAPPRapport Therapeutics, Inc. Life Sciences 0.05 $1.3B Unlock rating and forecasts
143 TYRATyra Biosciences, Inc. Life Sciences 0.12 $1.3B Unlock rating and forecasts
144 LBRXLB PHARMACEUTICALS INC Life Sciences 0.21 $1.2B Unlock rating and forecasts
145 TSHATaysha Gene Therapies, Inc. Life Sciences 0.03 $1.2B Unlock rating and forecasts
146 OMEROMEROS CORP Life Sciences 0.15 $1.2B Unlock rating and forecasts
147 OPKOPKO HEALTH, INC. Life Sciences 0.39 $1.1B Unlock rating and forecasts
148 GHRSGH Research PLC Life Sciences 0.25 $1.1B Unlock rating and forecasts
149 BCAXBicara Therapeutics Inc. Life Sciences 0.17 $1.1B Unlock rating and forecasts
150 AMPHAmphastar Pharmaceuticals, Inc. Life Sciences 0.40 $1.1B Unlock rating and forecasts
101–150 of 296 Previous Next
Since the previous run

Rating changes

▲ 171▼ 378
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-16) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected absolute price move over the horizon, market included. This is the number a price target is built from. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.